Discounted Cash Flow
Chemomab Therapeutics Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | — | $-9.5m | — | — | — |
| 2018 | — | $-12.7m (-33.5%) | — | — | — |
| 2019 | — | $-27.1m (-114.3%) | $-16.6m | — | — |
| 2020 | — | $-11.6m (57.2%) | $-12.7m (23.0%) | — | — |
| 2021 | — | $12.5m (207.5%) | $-12.6m (1.0%) | — | $0.06 |
| 2022 | $0 | $27.6m (121.6%) | $-20.4m (-62.0%) | — | $0.12 (101.7%) |
| 2023 | $0 | $24.2m (-12.4%) | $-23.6m (-15.5%) | — | $0.10 (-14.9%) |
| 2024 | $0 | $13.9m (-42.4%) | $-15.4m (34.8%) | — | $0.04 (-62.1%) |
| 2025 | $0 | $9.0m (-35.5%) | $-11.1m (27.6%) | — | $0.02 (-53.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.